“…Different approaches were then implemented to solve this problem: from the use of different E. coli strains, such as DH5α, Rosetta (DE 3 ) pLysS, BL21 and Krx (strain Krx allowed higher expression levels) to control of the temperature growth (TEVp is prone to aggregate at higher temperatures) (Fang et al, 2007;Kapust and Waugh, 1999;Kapust et al, 2002aKapust et al, , 2001Miladi et al, 2011;Van Den Berg et al, 2006;Wu et al, 2009). TEVp was also obtained following refolding of the material recovered from inclusion bodies (Blommel and Fox, 2007;Lucast et al, 2001) and through the widely used approach of fusing it to solubility tags such as poly-histidine or polyarginine tags (Kapust and Waugh, 1999;Kapust et al, 2001;Kapust et al, 2002b), Maltosebinding protein (MBP) and glutathione S-transferase (GST) (Blommel and Fox, 2007;Kapust and Waugh, 1999;Sun et al, 2012), Thioredoxin (TRX) (Kapust and Waugh, 1999), Streptag II (Miladi et al, 2011), hyper-acidic protein fusion partners (Zou et al, 2008), SUMO (Zou et al, 2008), the N-utilization substance (NusA) (Zou et al, 2008), superfolded GFP or chaperone proteins (Fang et al, 2007). Combining two or more of these variables it is now possible to obtain high scale production of soluble active and highly pure TEVp of up to 300-400 mg/L from bacterial cultures (Blommel and Fox, 2007;Wu et al, 2009).…”